shenle

used to reduce proteinuria and TCM syndrome in patients with IgA nephropathy

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	IGA Glomerulonephritis (IGA Nephropathy) 12/01/2006 - "[Prospective, multi-centered, randomized and controlled trial on effect of Shenle Capsule in treating patients with IgA nephropathy of Fei-Pi qi-deficiency syndrome]." 12/01/2006 - "To observe the effect and safety of Chinese compound Shenle Capsule (SC) in treating IgA nephropathy patients of Fei-Pi qi-deficiency syndrome (FPQD). "
2.	Glomerulonephritis 05/01/2002 - "[Clinical observation on effect of shenle capsule in treating mesangial proliferating glomerulonephritis]." 05/01/2002 - "To study the therapeutic effect of Shenle capsule (SLC) in treating mesangial proliferating glomerulonephritis (MsPGN) and to explore its therapeutic mechanism and clinical indication. "
3.	Proteinuria 12/01/2000 - "Shenle and Fragmin could significantly reduce the blood pressure, proteinuria, serum creatinine and lipids, alleviate the pathologic change of kidney tissue, decrease the type IV collagen, MMP-9 deposition. " 12/01/2000 - "After being treated with Shenle (4 g.kg-1.d-1) or Fragmin (1000 IU.kg-1.d-1) for 20 weeks, the blood pressure, proteinuria, serum creatinine, lipids, renal pathological change of remnant kidney of the model animals were examined, and the mRNA expression of MMP-9, TIMP-1 and type IV collagen in the remnant kidney were also detected. "

1.	Capsules (Microcapsules)
2.	Therapeutic Uses
3.	Collagen Type IV (Type IV Collagen)
4.	Tissue Inhibitor of Metalloproteinase-1
5.	Dalteparin (Dalteparin Sodium)
6.	Messenger RNA (mRNA)
7.	Lipids
8.	Creatinine